NF-κB Explained: The Switch Behind Inflammation Research
What NF-kB actually is, how IkB and the IKK complex throw the switch, why no direct NF-kB inhibitor has been approved, and what the published KPV, LL-37 and GHK-Cu work really measured.
Archive
Category: Recovery & Repair Research
Research summaries for peptides studied in tissue-repair, wound-model and inflammation research, including BPC-157, KPV, LL-37, ARA-290 and the KLOW blend, with what is established and what is not.
Angiogenesis and VEGF Explained: How New Blood Vessels Form
VEGF and angiogenesis explained: how new blood vessels form, the VEGF receptors, why cancer drugs block it, and the peptide research angle.
Antimicrobial Peptides Explained: Defensins, Cathelicidins and LL-37
Antimicrobial peptides explained: defensins, cathelicidins like LL-37 and other host-defence peptides, how they kill microbes, and why they're studied.
KLOW Peptide Blend: What’s Inside and What the Research Shows
KLOW peptide explained: the GHK-Cu, BPC-157, TB-500 and KPV blend, what each component's research shows, KLOW vs GLOW, and how to verify a blend COA in Canada.
BPC-157 Safety: What Toxicology, Human Data and Regulators Say
Is BPC-157 safe? What animal toxicology, the three small human pilot studies, the cancer question and 2026 decisions by Health Canada and the FDA actually show.
ARA-290 (Cibinetide): What the Research Shows
ARA-290 (cibinetide) explained: the EPO-derived peptide that targets the innate repair receptor, its small-fibre neuropathy trials, and Canadian sourcing.
KPV Peptide: What the Research Shows
KPV explained: the anti-inflammatory tripeptide from alpha-MSH, the PepT1 colitis studies, KPV blends, and what to check when sourcing in Canada.
LL-37 Peptide: What the Research Shows
LL-37 explained: the only human cathelicidin, how vitamin D switches it on, its immune-signalling roles studied at UBC, and sourcing it in Canada.